[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370408-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370408-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-myeloid-ifn-gamma-response-gene-signature-correlates-with-cancer-prognosis-research-article","A myeloid IFN gamma response gene signature correlates with cancer prognosis - Research article","","IFN-γ cytokine shows a dual role in anti-tumor immunity, yet its cross-cancer prognostic value and effects on treatment response remain unclear. This study performs a pan-cancer analysis of IFN-γ response genes, generating the IFN-γ Response Gene Network Signature (IFGRNS) score. Using multiple datasets and single-cell profiling, the work links IFGRNS to disease-specific survival, tumor pathology, genomic features, tumor mutation burden, and the immune microenvironment, and validates results with anti-PD1 therapy in a murine PAN02 model.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-myeloid-ifn-gamma-response-gene-signature-correlates-with-cancer-prognosis-research-article/370408/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-myeloid-ifn-gamma-response-gene-signature-correlates-with-cancer-prognosis-research-article/370408.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the IFGRNS score and how was it constructed?","Question",{"text":63,"@type":64},"The IFGRNS score is derived from an IFN-γ Response Gene Network Signature. It uses expression of 46 IFN-γ response genes identified as prognostic across multiple datasets to build a score for analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the IFGRNS score relate to survival across cancer types?",{"text":68,"@type":64},"Higher IFGRNS scores generally correlate with worse survival outcomes in most cancer types. The prognostic impact varies with cancer type, tumor pathology, and the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study show about immune cells and anti-PD1 therapy?",{"text":72,"@type":64},"Single-cell analysis indicates myeloid cells, especially M2 macrophages, contribute to high IFGRNS expression. In a PAN02 murine model, anti-PD1 therapy reduces tumor size and IFGRNS expression in M2 macrophages, supporting the clinical relevance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370408,1790263981,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10.1002/ctm2.70139  \nRESEARCH ARTICLE  \nA myeloid IFN gamma response gene signature correlates with cancer prognosis  \nYuchao Zhang1   Asma Khanniche2  Yizhe Li1 Hailong Wang1,2  Hongyu Zhang1  Xiaoxue Li1  \nZhenchuan Wu1,2 Landian Hu1,2, 3   \nXiangyin Kong1, 4  \n1 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China  \n2ANDA Biology Medicine Development (Shenzhen) Co., LTD, Shenzhen, China  \n3 Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China  \n4 School of Life Science and Technology, ShanghaiTech University, Shanghai, China  \nCorrespondence  \nXiangyin Kong, Landian Hu, andYuchao Zhang, CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China.  \n[Email:](Email: xykong@sibs.ac.cn)[ xykong@sibs.ac.cn](Email: xykong@sibs.ac.cn), [ldhu2013@163.com](ldhu2013@163.com), and [zhangyuchao@sibs.ac.cn](zhangyuchao@sibs.ac.cn)  \nGraphical Abstract  \n1. IFGRNS score is a novel prognostic biomarker upregulated in myeloid lineage cells.  \n2. IFGRNS score correlates with survival outcomes across multiple cancer types.  \n3. IFGRNS score is associated with tumour pathology and immune microenvironment.  \n4. IFGRNS score predicts immunotherapy response, with potential for clinical application.  \nClin. Transl. Med. 2025;15:e70139 .  \n[https://doi.org/10.1002/ctm2.70139](https://doi.org/10.1002/ctm2.70139)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70139  \nRESEARCH ARTICLE  \nA myeloid IFN gamma response gene signature correlates with cancer prognosis  \nYuchao Zhang1   Asma Khanniche2  Yizhe Li1 Hailong Wang1,2  Hongyu Zhang1  Xiaoxue Li1  \nZhenchuan Wu1,2 Landian Hu1,2, 3   \nXiangyin Kong1, 4  \n1 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China  \n2ANDA Biology Medicine Development (Shenzhen) Co., LTD, Shenzhen, China  \n3 Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China  \n4 School of Life Science and Technology, ShanghaiTech University, Shanghai, China  \nCorrespondence  \nXiangyin Kong, Landian Hu, and Yuchao Zhang, CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China.  \n[Email:](Email: xykong@sibs.ac.cn)[ xykong@sibs.ac.cn](Email: xykong@sibs.ac.cn), [ldhu2013@163.com](ldhu2013@163.com), and [zhangyuchao@sibs.ac.cn](zhangyuchao@sibs.ac.cn)  \nFunding information  \nKey Research Program of Frontier Sciences of Chinese Academy of Sciences, Grant/Award Number:  \nQYZDJ-SSW-SMC017; National Key R&D Program of China, Grant/Award Number: 2021YFA0805201; Science and Technology Service Network Initiative, Grant/Award Number: KFJ-STS-QYZD-187; Strategic Priority Research Program of Chinese Academy of Sciences, Grant/Award Number: XDA12010204  \nAbstract  \nBackground: The IFN-γ cytokine plays a dual role in anti-tumor immunity, enhancing immune defense against cancer cells while promoting tumor survival and progression. Its influence on prognosis and therapeutic responses across cancer types remains unclear.  \nObjective: This study aimed to perform a pan-cancer analysis ofIFN-γ response genes to determine their prognostic significance and evaluate their impact on clinical outcomes and anti-PD1 immunotherapy responses.  \nMethods: Using multiple datasets, 46 IFN-γ response genes were identified as prognostic for disease-specific survival, and their expression was used to construct the IFN-γ Response Gene Network Signature (IFGRNS) score. The prognostic and therapeutic relevance of the IFGRNS score was assessed across cancer types, considering tumor pathology, genomic alterations, tumor mutation burden, and microenvironment. Single-cell transcriptomic ","cbCaijOuxYEwa7Il","https://ap.wps.com/l/cbCaijOuxYEwa7Il","pdf",7893757,23,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is the IFGRNS score and how was it constructed?\",\"answer\":\"The IFGRNS score is derived from an IFN-γ Response Gene Network Signature. It uses expression of 46 IFN-γ response genes identified as prognostic across multiple datasets to build a score for analysis.\"},{\"question\":\"How does the IFGRNS score relate to survival across cancer types?\",\"answer\":\"Higher IFGRNS scores generally correlate with worse survival outcomes in most cancer types. The prognostic impact varies with cancer type, tumor pathology, and the tumor microenvironment.\"},{\"question\":\"What does the study show about immune cells and anti-PD1 therapy?\",\"answer\":\"Single-cell analysis indicates myeloid cells, especially M2 macrophages, contribute to high IFGRNS expression. In a PAN02 murine model, anti-PD1 therapy reduces tumor size and IFGRNS expression in M2 macrophages, supporting the clinical relevance.\"}]","A myeloid IFN gamma response gene signature correlates with cancer prognosis - Research article | PDF",1790188375,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e4183b56bfb041bd5c03a7f4c6b58a9.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9956c53a64f74f8be7243a756118bcd5.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8ecb3e88f15b6f2dbda0bf7b7b3b869.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97fd31b7466254fc812dc94fdf8ad6f.webp",980,1287]